Over the last few decades, biomedical research has unraveled a plethora of pathophysiological steps putatively important for human disease development. But it was only in the last few years that a broader translation from basic research efforts to clinical medicine has indeed occurred. This was largely made possible by the close cooperation of basic researchers and clinical investigators, aiming at the development of truly effective therapeutics. Inflammatory skin diseases such as psoriasis and atopic dermatitis serve as an example of this successful bench-to-bedside approach. Currently, more and more therapies are approved as a result of this scientific approach, and many more are on their way.
Nevertheless, a stand-alone meeting in which inflammatory skin diseases and the translational revolution that we are currently experiencing take center stage has been lacking. After three very successful meetings in Vienna in 2014 and 2018 and in New York City in 2016, we have again taken upon the task of organizing such an important meeting in order to continue this path of therapeutic revolution and extend to other inflammatory skin diseases. We want to discuss new concepts and new developments in the field of inflammatory skin diseases and to devise and explore new therapeutic strategies. For the last two meetings, we had been able to attract true leaders in their fields, and we had approximately 600 participants from all over the world at the 2018 meeting in Vienna. We have now established this conference on an every two-year basis, with the next meeting taking place in New York City, USA, November 3-6, 2021.